Drug Trial Radar · NCT03031210
Twice Daily Treatment With Amoxicillin for Non-severe Community Acquired Pneumonia.
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,370
Planned (sponsor's estimate)
Start
Jun 11, 2017
Primary completion
Jun 1, 2027
Study completion Jun 1, 2027
Sponsor
- Lead sponsor
- St. Justine's HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 25, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 3 months, up to 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The aim of this study will be to evaluate whether a twice-daily antibiotic regimen is non-inferior to a thrice-daily regimen for the treatment of non-severe community acquired pneumonia in children presenting at a paediatric Emergency Department (ED).
Conditions
- Community-acquired Pneumonia
Interventions
AmoxicillinDrug
(90 mg/kg/day) twice daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical failure within 10 days of enrolmentTime frame: Day 10 (after enrolment)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
CHU Sainte-Justine
Montreal, Quebec, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.